分化型甲状腺癌患者甲状腺球蛋白持续升高：十年回顾
Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.
作者信息
Khan Sarah, Prabhushankar Roopashree, Leary Emily, Khan Uzma Z
机构信息
Sarah Khan is at the University of Missouri School of Medicine.
Roopashree Prabhushankar, MD, is at Desert Kidney Associates, Endocrinology, Mesa, Arizona.
出版信息
Mo Med. 2017 Sep-Oct;114(5):387-393.
Abstract
Differentiated Thyroid Cancer (DTC) is increasing in prevalence due to better diagnostic tools and excellent long-term survival. This study is to understand the outcome of twenty-six patients with DTC over a period of 10 years after the initial treatment with surgery and radioiodine therapy. Our study analysis showed no deaths, and indicated that older men were more likely to have persistent disease. Further studies are needed to focus on cost effective long-term management of DTC.
摘要
由于诊断工具的改进和出色的长期生存率，分化型甲状腺癌（DTC）的患病率正在上升。本研究旨在了解26例DTC患者在接受手术和放射性碘治疗的初始治疗后10年的预后情况。我们的研究分析显示无死亡病例，并表明老年男性更易出现持续性疾病。需要进一步开展研究，重点关注DTC具有成本效益的长期管理。
相似文献
1
Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.分化型甲状腺癌患者甲状腺球蛋白持续升高：十年回顾
Mo Med. 2017 Sep-Oct;114(5):387-393.
2
Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.分化型甲状腺癌（DTC）的持续风险分层——放射性碘（RAI）消融术前刺激血清甲状腺球蛋白（Tg），这是M0患者癌症复发的最有力风险因素。
Endokrynol Pol. 2016;67(1):2-11. doi: 10.5603/EP.2016.0001.
3
Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.放射性碘难治性分化型甲状腺癌的治疗结果及预后因素
Oncologist. 2016 Jan;21(1):50-8. doi: 10.1634/theoncologist.2015-0107. Epub 2015 Dec 16.
4
Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.分化型甲状腺癌伴甲状腺球蛋白升高及阴性诊断性放射性碘全身扫描的处理。
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):438-47. doi: 10.1016/j.clon.2010.05.005. Epub 2010 Jun 18.
5
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.接受重组人促甲状腺激素或甲状腺激素停药后低活度¹³¹I 放射性碘甲状腺残余消融治疗的分化型甲状腺癌患者，在 10 年随访后具有相同的结果。
J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137. Epub 2013 Apr 26.
6
Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.甲状腺切除术后4周的甲状腺球蛋白检测可预测低危甲状腺乳头状癌的预后。
Clin Chem Lab Med. 2005;43(8):843-7. doi: 10.1515/CCLM.2005.142.
7
Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.低但可测量的刺激血清甲状腺球蛋白水平<2μg/L常常预示分化型甲状腺癌患者反应不完全。
Endocr Res. 2014;39(4):157-63. doi: 10.3109/07435800.2013.865211. Epub 2014 Jan 24.
8
Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.在瑞典的一个县中分化型甲状腺癌——长期结果和生活质量。
Acta Oncol. 2010 May;49(4):454-9. doi: 10.3109/02841860903544600.
9
Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.分化型甲状腺癌患者不明原因的甲状腺球蛋白升高作为辅助放射性碘治疗的指征：一项前瞻性多中心研究。
J Nucl Med. 2021 Jan;62(1):62-68. doi: 10.2967/jnumed.120.243642. Epub 2020 May 1.
10
Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer.（131）I 治疗的疗效分析及消融前刺激甲状腺球蛋白对分化型甲状腺癌肺转移的预测价值。
Ann Endocrinol (Paris). 2013 Feb;74(1):40-4. doi: 10.1016/j.ando.2012.11.007. Epub 2013 Jan 18.
本文引用的文献
1
Multistage carcinogenesis and the incidence of thyroid cancer in the US by sex, race, stage and histology.美国按性别、种族、分期和组织学分类的多阶段致癌作用与甲状腺癌发病率
BMC Public Health. 2015 Aug 18;15:789. doi: 10.1186/s12889-015-2108-4.
2
Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.甲状腺乳头状癌伴远处转移治疗结果的长期随访
Medicine (Baltimore). 2015 Jul;94(26):e1063. doi: 10.1097/MD.0000000000001063.
3
Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance?甲状腺球蛋白抗体状态与分化型甲状腺癌：对预后和监测意味着什么？
Curr Opin Oncol. 2015 Jan;27(1):26-32. doi: 10.1097/CCO.0000000000000149.
4
Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer.选择的远处转移型甲状腺乳头癌患者的无治疗长期生存。
Endocr Connect. 2014 Dec;3(4):207-14. doi: 10.1530/EC-14-0097. Epub 2014 Oct 14.
5
Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members.持续性可检测到甲状腺球蛋白且诊断性放射性碘全身扫描阴性患者的诊疗趋势：美国甲状腺协会成员调查
Thyroid. 2014 Oct;24(10):1501-7. doi: 10.1089/thy.2014.0043. Epub 2014 Sep 5.
6
The age factor in survival of a population cohort of well-differentiated thyroid cancer.年龄因素对分化型甲状腺癌人群队列生存的影响。
Endocr Connect. 2013 Sep 23;2(3):154-60. doi: 10.1530/EC-13-0056. Print 2013.
7
Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.甲状腺球蛋白阳性、无法定位的甲状腺癌的保守治疗。
Head Neck. 2014 Feb;36(2):155-7. doi: 10.1002/hed.23272. Epub 2013 Jun 1.
8
Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis.分化型甲状腺癌与桥本甲状腺炎共存的患者疾病侵袭性较弱，预后较好。
J Clin Endocrinol Metab. 2013 Jun;98(6):2409-14. doi: 10.1210/jc.2013-1309. Epub 2013 Apr 22.
9
Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies.在存在抗甲状腺球蛋白自身抗体的情况下，通过液相色谱-串联质谱法测量血清和血浆中的甲状腺球蛋白。
Clin Chem. 2013 Jun;59(6):982-90. doi: 10.1373/clinchem.2012.195594. Epub 2013 Feb 8.
10
Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome.慢性淋巴细胞性甲状腺炎合并甲状腺乳头状癌的共存：临床表现和预后结果。
J Korean Med Sci. 2012 Aug;27(8):883-9. doi: 10.3346/jkms.2012.27.8.883. Epub 2012 Jul 25.
Zotero 插件